Horizon Usher Foundation, in collaboration with Sepul Bio and Laboratoires Théa, is hosting its first open webinar to present the latest scientific advances in the fight against retinitis pigmentosa and Usher syndrome.
The event will take place online via Zoom on February 4, 2026, at 7:00 PM (CET).
Important : The webinar will be conducted entirely in French, but a written translation in the language of your choice will be provided.
Register here.
Why This Webinar
In December 2024, Sepul Bio announced the launch of the LUNA Study, a phase 2b clinical trial designed to evaluate Ultevursen, an innovative RNA therapy, in individuals with retinitis pigmentosa caused by USH2A gene mutations.
The goal is to provide real hope for thousands of patients. The LUNA Study will assess Ultevursen’s effectiveness in slowing, or even stabilizing, vision loss.
By bringing together researchers, specialists, and the community, this webinar will help participants better understand:
-
The scientific and medical challenges of the trial
-
What these advances mean for patients, families, and caregivers
-
The upcoming challenges and the tangible hopes linked to this therapy
Speakers — Leading Experts
The webinar will feature:
-
Prof. Isabelle Audo — expert in retinal diseases, Institut de la Vision, Paris
-
Dr. Isabelle Meunier — specialist in hereditary retinal dystrophies, CHU Montpellier
They will present the current state of knowledge, share the latest research findings, and answer participants’ questions live.
Practical Information
-
When: February 4, 2026 — 7:00 PM (CET)
-
Where: Online, via Zoom
-
Language: French (with written translation available)
-
Registration: Required — Register here.
Who Should Attend
This webinar is intended for:
-
Anyone affected by retinitis pigmentosa or Usher syndrome
-
Families, caregivers, healthcare professionals, and members of the scientific community
-
Anyone seeking information or wishing to get involved in research and support for this cause
